Renaissance Technologies's REGN Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 275,162 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $154.72 M, representing 0.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in REGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2017, adding 485,600 shares. Largest reduction occurred in Q1 2021, reducing 839,800 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +234,763 | Add 0.00% | 234,762 | $224.88 |
| Q3 2013 | +14,759 | Add 6.29% | 249,521 | $312.87 |
| Q4 2013 | -179,459 | Reduce 71.92% | 70,062 | $275.24 |
| Q1 2014 | -70,062 | Sold Out | 70,062 | $0.00 |
| Q2 2014 | +2,862 | New Buy | 2,862 | $282.32 |
| Q3 2014 | +23,700 | Add 828.09% | 26,562 | $360.52 |
| Q4 2014 | -26,562 | Sold Out | 26,562 | $0.00 |
| Q1 2015 | +167,488 | New Buy | 167,488 | $451.48 |
| Q2 2015 | -167,488 | Sold Out | 167,488 | $0.00 |
| Q4 2015 | +107,262 | New Buy | 107,262 | $542.87 |
| Q1 2016 | +109,700 | Add 102.27% | 216,962 | $360.44 |
| Q2 2016 | -6,200 | Reduce 2.86% | 210,762 | $349.23 |
| Q3 2016 | -210,762 | Sold Out | 210,762 | $0.00 |
| Q4 2016 | +250,560 | New Buy | 250,560 | $367.09 |
| Q1 2017 | -18,484 | Reduce 7.38% | 232,076 | $387.51 |
| Q2 2017 | -232,076 | Sold Out | 232,076 | $0.00 |
| Q3 2017 | +93,962 | New Buy | 93,962 | $447.12 |
| Q4 2017 | +485,600 | Add 516.80% | 579,562 | $375.96 |
| Q1 2018 | -97,092 | Reduce 16.75% | 482,470 | $344.36 |
| Q2 2018 | -1,008 | Reduce 0.21% | 481,462 | $344.99 |
| Q3 2018 | -213,400 | Reduce 44.32% | 268,062 | $404.04 |
| Q4 2018 | +81,800 | Add 30.52% | 349,862 | $373.50 |
| Q1 2019 | -141,600 | Reduce 40.47% | 208,262 | $410.62 |
| Q2 2019 | +129,700 | Add 62.28% | 337,962 | $313.00 |
| Q3 2019 | +60,856 | Add 18.01% | 398,818 | $277.40 |
| Q4 2019 | -110,418 | Reduce 27.69% | 288,400 | $375.48 |
| Q1 2020 | +198,962 | Add 68.99% | 487,362 | $488.29 |
| Q2 2020 | +402,738 | Add 82.64% | 890,100 | $623.65 |
| Q3 2020 | +182,262 | Add 20.48% | 1.07 M | $559.78 |
| Q4 2020 | -167,410 | Reduce 15.61% | 904,952 | $483.11 |
| Q1 2021 | -839,800 | Reduce 92.80% | 65,152 | $473.14 |
| Q2 2021 | -65,152 | Sold Out | 65,152 | $0.00 |
| Q3 2021 | +101,262 | New Buy | 101,262 | $605.18 |
| Q4 2021 | +181,700 | Add 179.44% | 282,962 | $631.52 |
| Q1 2022 | -3,100 | Reduce 1.10% | 279,862 | $698.42 |
| Q2 2022 | +303,200 | Add 108.34% | 583,062 | $591.13 |
| Q3 2022 | -374,662 | Reduce 64.26% | 208,400 | $688.87 |
| Q4 2022 | -16,959 | Reduce 8.14% | 191,441 | $0.72 |
| Q1 2023 | -76,541 | Reduce 39.98% | 114,900 | $0.82 |
| Q2 2023 | -26,700 | Reduce 23.24% | 88,200 | $0.72 |
| Q3 2023 | +73,862 | Add 83.74% | 162,062 | $822.96 |
| Q4 2023 | +81,000 | Add 49.98% | 243,062 | $878.29 |
| Q1 2024 | -77,700 | Reduce 31.97% | 165,362 | $962.49 |
| Q2 2024 | +19,800 | Add 11.97% | 185,162 | $1051.03 |
| Q3 2024 | +26,261 | Add 14.18% | 211,423 | $1051.24 |
| Q4 2024 | +36,320 | Add 17.18% | 247,743 | $712.33 |
| Q1 2025 | -168,842 | Reduce 68.15% | 78,901 | $634.23 |
| Q2 2025 | -33,839 | Reduce 42.89% | 45,062 | $525.00 |
| Q3 2025 | +230,100 | Add 510.63% | 275,162 | $562.27 |
Renaissance Technologies's Regeneron Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 234,762 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Regeneron Pharmaceuticals, Inc. (REGN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q4 2017, adding 579,562 shares worth $217.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 275,162 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $154.72 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.20% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 1,072,362 shares, as reported at the end of Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.